Publication Date
7-18-2022
Keywords
hematology, malignancy, COVID-19, SARS-CoV-2, mRNA vaccine, antibody, seroconversion, blood cancer, preventive care
Abstract
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics
Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus.
Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID-19 vaccine (P < 0.00001). Response to 3V was significantly associated with the 3V vaccine type (P = 0.0006), previous COVID-19 infection (P = 0.0453), and malignancy diagnosis (P < 0.0001). Likelihood of seroconversion (-/+) after 3V was higher in the group of patients with multiple myeloma or related disorders compared to patients with lymphoid leukemias (odds ratio: 8.22, 95% CI: 2.12–31.79; P = 0.0008).
Conclusions: A third COVID-19 vaccination is effective in producing measurable seroconversion in many patients with hematologic malignancies. Oncologists should actively encourage all their patients, especially those with multiple myeloma, to receive a 3V, given the high likelihood of seroconversion.
Recommended Citation
Thompson MA, Hallmeyer S, Fitzpatrick VE, Liao Y, Mullane MP, Medlin SC, Copeland K, Weese JL. Real-world third COVID-19 vaccine dosing and antibody response in patients with hematologic malignancies. J Patient Cent Res Rev. 2022;9:149-57. doi: 10.17294/2330-0698.1952
Included in
Allergy and Immunology Commons, Community Health and Preventive Medicine Commons, Health and Medical Administration Commons, Health Services Research Commons, Hemic and Immune Systems Commons, Hemic and Lymphatic Diseases Commons, Infectious Disease Commons, Medical Immunology Commons, Oncology Commons, Patient Safety Commons
Submitted
January 30th, 2022
Accepted
April 20th, 2022
